Crystal Adam 4

What Happened
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), sold 54,345 shares on February 25, 2026. The weighted average sale price was $12.77 per share (range $12.61–$13.09), for total proceeds of approximately $694,208. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: 2026-02-25 (Period of Report: 2026-02-25; Filing date: 2026-02-27). Filing appears timely.
• Price: Weighted average $12.77; sales ranged $12.61 to $13.09 per share. (Footnote: detailed breakdown by price available upon request to the SEC, issuer, or a security holder.)
• Shares sold: 54,345; Proceeds: ~$694,208.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes: Transaction executed under a Rule 10b5-1 trading plan adopted October 27, 2025 (F1). Footnote F2 explains the weighted average and price range. Remark: Exhibit 24 (Power of Attorney) attached.

Context
This was an open-market sale under a pre-established 10b5-1 plan, which often indicates the trades were pre-scheduled rather than triggered by recent company developments. Sales are common and generally less informative about future company performance than purchases; the filing provides no explanation of motive.